AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy ; volume:8 ; number:1 ; day:1 ; month:8 ; year:2015 ; pages:1-4 ; date:12.2015
Journal of hematology & oncology ; 8, Heft 1 (1.8.2015), 1-4, 12.2015
- Urheber
-
Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-015-0188-3
- URN
-
urn:nbn:de:101:1-2021081621591530771719
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wu, Jingjing
- Fu, Jiaping
- Zhang, Mingzhi
- Liu, Delong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
STAT1 signaling shields T cells from NK cell-mediated cytotoxicity
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific antibodies come to the aid of cancer immunotherapy
KIR-HLA footprints and NK cell-mediated recognition of HIV-1
Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell‐Mediated Tumor Immunotherapy
Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
STAT1 signaling shields T cells from NK cell-mediated cytotoxicity
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific antibodies come to the aid of cancer immunotherapy
KIR-HLA footprints and NK cell-mediated recognition of HIV-1
Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell‐Mediated Tumor Immunotherapy
Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
STAT1 signaling shields T cells from NK cell-mediated cytotoxicity
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific antibodies come to the aid of cancer immunotherapy
KIR-HLA footprints and NK cell-mediated recognition of HIV-1